NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
NuVasive Stock Up 1.8 %
Shares of NASDAQ:NUVA opened at $53.49 on Friday. The firm has a fifty day simple moving average of $50.75 and a two-hundred day simple moving average of $52.72. NuVasive has a 12 month low of $45.45 and a 12 month high of $64.43. The company has a current ratio of 1.17, a quick ratio of 0.70 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $2.78 billion, a PE ratio of -66.86, a price-to-earnings-growth ratio of 2.09 and a beta of 1.14.
Analysts Set New Price Targets
Several equities analysts recently commented on the stock. Piper Sandler reduced their target price on shares of NuVasive from $80.00 to $60.00 and set an "overweight" rating on the stock in a report on Thursday, August 4th. Truist Financial lowered their target price on NuVasive to $63.00 in a research note on Friday, July 22nd. Morgan Stanley decreased their price target on NuVasive from $62.00 to $54.00 and set an "equal weight" rating on the stock in a research note on Friday, July 15th. Finally, Canaccord Genuity Group increased their price objective on NuVasive from $50.00 to $55.00 in a research note on Friday, August 5th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, NuVasive has a consensus rating of "Hold" and an average price target of $61.75.